electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
electroCore, Inc. (ECOR) to report Q4 and year-end 2023 financial results on March 13, 2024. Conference call scheduled to discuss the results.
03/05/2024 - 04:05 PM
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, March 13, 4:30 PM EST located here electroCore Earnings Webcast
About electroCore, Inc.
For more information, visit www.electrocore.com .
Contact:
When will electroCore, Inc. report its financial results for Q4 and year-end 2023?
electroCore, Inc. will report its financial results for the fourth quarter and year ended December 31, 2023, on Wednesday, March 13, 2024.
What is the ticker symbol for electroCore, Inc.?
The ticker symbol for electroCore, Inc. is ECOR.
When is the conference call scheduled to discuss the financial results?
The conference call to discuss the financial results is scheduled for Wednesday, March 13, 2024, at 4:30 PM EST.
How can I join the webcast for electroCore's earnings?
You can join the webcast for electroCore's earnings by visiting the 'electroCore Earnings Webcast' link provided.
ECOR Rankings
#411 Ranked by Stock Gains
ECOR Stock Data
Industry
Electromedical and Electrotherapeutic Apparatus Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
Country
United States
About ECOR
electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.
